Treatment News : World Health Organization Recommends Earlier HIV Treatment

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » July 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

July 2, 2013

World Health Organization Recommends Earlier HIV Treatment

The World Health Organization (WHO) has revised its treatment guidelines for people living with HIV worldwide, recommending they begin antiretroviral (ARV) therapy when their CD4 count hits 500 or below, as opposed to the previous benchmark of 350, The New York Times reports. WHO released the new guidelines on the opening day of the International AIDS Society 2013 conference in Kuala Lumpur.  

WHO also recommended that various subgroups of HIV-positive people receive ARVs regardless of CD4 count, including all children younger than 5, all pregnant and nursing women, and anyone in an ongoing relationship with an HIV-negative partner. The agency continues to advise that all of those who are HIV positive and living with active tuberculosis (TB) or with hepatitis B virus (HBV) receive ARVs.

A further recommendation is that all adults should begin treatment with a once-a-day, single pill combination therapy containing Viread (tenofovir), Sustiva (efavirenz) and either Epivir (lamivudine) or Emtriva (emtricitabine). (Atripla contains tenofovir, efavirenz and emtricitabine; a generic-based version of the combo uses lamivudine instead of emtricitabine—the two meds operate similarly—and has received tentative approval by the FDA.)

The new guidelines will extend drug eligibility from the current 17 million to 26 million people in poor and middle-income countries. WHO estimates that nearly 10 million people are currently receiving ARVs worldwide, out of a total 34 million living with the virus.

WHO projects that the new guidelines could prevent an additional 3 million deaths as well as 3.5 million new infections by 2025.

To read the Times story, click here.

To read the WHO release, click here.

Search: HIV treatment, antiretrovirals, World Health Organization, WHO, International AIDS Society 2013 conference, tuberculosis, TB, hepatitis B virus, HBV, Viread, tenofovir, Sustiva, efavirenz, Epivir, lamivudine, Emtriva, emtricitabine, Atripla.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    chrisf
    san jose
    California


    soy_Ric
    Rochester
    New York


    ernienyc
    Bronx
    New York


    pozsmith1
    East Bay
    California
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.